In order to investigate the effect of N-tosyl-L-phenylalnylchloromethyl
ketone (
TPCK) and
dexamethasone (Dex) on expression of nuclear
transcription factor-kappaB (
NF-kappaB) in childhood
acute lymphoblastic leukemia (ALL) and its significance, so as to provide the experimental basis for corresponding clinical treatment of ALL, in which
NF-kappaB is taken as a target. The
biotin-
streptavidin method was used to detect the expression of
NF-kappaB P65
protein and the effects of
TPCK and Dex at clinically relevant dosage on activity of
NF-kappaB P65
protein in 20
childhood ALL patients. The results indicated that the expression of
NF-kappaB P65
protein was strongly diminished and reached to negative level at 2 hours by treatment with 40 micromol/L
TPCK, the positive expression of
NF-kappaB P65
protein was (2.5 +/- 1.6)%.
TPCK had a time-dependent inhibitory effect on ALL cells cultured in vitro. The expression of
NF-kappaB P65
protein in ALL cells was strongly inhibited by clinically relevant concentration of
dexamethasone 5.0 microg/ml for 24 hours in vitro. The positive expression was (25.0 +/- 3.0)%, there was significant difference, as compared with untreated ALL cells (T=55, P<0.01). It is concluded that
TPCK and Dex can inhibit
NF-kappaB activity. Inhibition of
NF-kappaB activity may be one of the effect mechanism of
dexamethasone on ALL cells. Inhibition of
NF-kappaB conduction pathway may have a significant value in
childhood ALL treatment.